IGF1 and cancer: In a pilot clinical trial in 19 healthy volunteers (7 women and 12 men), 3 monthly FMD cycles (5 d per cycle) decreased risk factors/biomarkers such as body weight, serum glucose, IGF-I, trunk fat, and others associated with aging, diabetes, CVD, and cancer without major adverse effects (100).